Aardvark Therapeutics Investors Face Deadline to Join Lawsuit
News related to:Aardvark Therapeutics, Inc · 2 min read
NEW YORK, Sept. 11, 2026 /CourierPR/ -- Rosen Law Firm, a global investor rights law firm, has reminded investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a critical deadline in a securities fraud lawsuit. The law firm is urging shareholders who purchased the company's securities during a specific period to act quickly to join the class action lawsuit.
According to Rosen Law Firm, the lawsuit centers around alleged false and misleading statements made by the company and its officers during the period from February 13, 2025, to May 14, 2026. Specifically, the lawsuit claims that Aardvark failed to disclose that the drug ARD-101 was less safe than initially communicated to investors. This omission, the firm argues, overstated the clinical, regulatory, and commercial prospects of the drug.
The law firm notes that the Registration Statement issued in connection with Aardvark's initial public offering (IPO) on February 13, 2025, and subsequent statements made by the company throughout the class period were allegedly misleading. The lawsuit asserts that these statements misled investors, causing them to suffer financial losses when the truth about ARD-101's safety was revealed.
Rosen Law Firm has set a lead plaintiff deadline of October 13, 2026. Investors who purchased Aardvark securities during the class period are encouraged to act quickly to potentially recover damages. The firm emphasizes that investors may join the class action without any out-of-pocket costs, as the case is handled on a contingency basis.
Rosen Law Firm has a history of success in securities class action cases, having achieved the largest settlement against a Chinese company and ranking first in securities class action settlements in 2017. The firm has recovered billions of dollars for investors and secured over $438 million in 2019 alone.
The lawsuit alleges that Aardvark's failure to disclose material adverse information about ARD-101's safety and its clinical, regulatory, and commercial prospects has resulted in significant financial harm to investors. The firm encourages investors to take action to protect their rights and potentially recover their losses.